January 08, 2025 04:34 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Sheesh Mahal row: AAP leaders who were denied entry into CM's residence turn towards PM's house | Anna University sexual assault accused is a DMK supporter, not member: MK Stalin | Ajit Doval, Raja Dato discuss bilateral cooperation during India-Malaysia Security Dialogue | US President-elect Donald Trump threatens to use economic force to make Canada 51st US State, Justin Trudeau retorts sharply | Elon Musk raises concern on 'world population decline' including that of India, China | Indian-origin Anita Ananda might replace Justin Trudeau as Canadian PM | 'I won't bite': Kamala Harris tells Senator's husband as he refuses to shake hands with her | Centre announces memorial for Pranab Mukherjee, his daughter thanks PM Modi for 'gracious gesture' | Delhi assembly elections on Feb 5, results on Feb 8 | Allu Arjun visits boy injured during Pushpa 2 stampede in Hyderabad
Glenmark introduces higher strength FabiFlu to reduce pill burden of COVID-19 treatment

Glenmark introduces higher strength FabiFlu to reduce pill burden of COVID-19 treatment

Aug 06, 2020, at 10:31 pm

Mumbai/UNI: Pharma major Glenmark announced on Thursday that it has introduced a 400 mg version of oral antiviral FabiFlu, for treating mild to moderate COVID-19 in India.

Glenmark slashes price of COVID-19 drug FabiFlu to Rs. 75 per tablet

Glenmark slashes price of COVID-19 drug FabiFlu to Rs. 75 per tablet

Jul 13, 2020, at 11:52 pm

Mumbai:  Glenmark Pharmaceuticals, a research-led, integrated global pharmaceuticalcompany, has announced a price reduction of 27% for COVID-19 drug FabiFlu.

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

Jun 21, 2020, at 01:23 pm

New Delhi/IBNS: Amid the massive spike in number of cases, India-based pharmaceutical company 'Glenmark Pharmaceuticals' has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients having mild to moderate COVID-19 symptoms.